OncoImmunology · 2014 · 80 citations · 134 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCell-based ImmunotherapyCytokine-based TherapyImmunostimulatory TherapyTumor-infiltrating LymphocytesAdaptive Antitumor ImmunityAdoptive ImmunotherapyAntitumor Immune ActivationCellular ImmunotherapyDendritic Cell-t Cell InteractionT Cell ReceptorsT Cell-based ImmunotherapyTumor-specific T Cell Activation
Toll-like receptors (TLRs) are an evolutionarily conserved group of enzymatically inactive, single membrane-spanning proteins that recognize a wide panel of exogenous and endogenous danger signals. Besides constituting a crucial component of the innate immune response to bacterial and viral pathogens, TLRs appear to play a major role in anticancer immunosurveillance. In line with this notion, several natural and synthetic TLR ligands have been intensively investigated for their ability to boost tumor-targeting immune responses elicited by a variety of immunotherapeutic and chemotherapeutic interventions. Three of these agents are currently approved by the US Food and Drug Administration (FDA) or equivalent regulatory agencies for use in cancer patients: the so-called bacillus Calmette-Guérin, monophosphoryl lipid A, and imiquimod. However, the number of clinical trials testing the therapeutic potential of both FDA-approved and experimental TLR agonists in cancer patients is stably decreasing, suggesting that drug developers and oncologists are refocusing their interest on alternative immunostimulatory agents. Here, we summarize recent findings on the use of TLR agonists in cancer patients and discuss how the clinical evaluation of FDA-approved and experimental TLR ligands has evolved since the publication of our first Trial Watch dealing with this topic.
134
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
A Toll-like receptor recognizes bacterial DNA
Hiroaki Hemmi, Osamu Takeuchi, Taro Kawai et al. · Nature · 2000 · 6.4K citations
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Lena Alexopoulou, Agnieszka Czopik Holt, Ruslan Medzhitov et al. · Nature · 2001 · 6.1K citations
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert, L. Thomas, Igor Bondarenko et al. · New England Journal of Medicine · 2011 · 4.5K citations · Full text
Medicine, Oncology, Pharmacotherapy +12